U.S. regulators have expanded approval for Pfizer's COVID-19 vaccine,for children aged 12 to 15.
The FDA expanded its emergency authorization after reviewing clinical data, which showed the vaccine's efficacy to be 100 percent, and that it's well tolerated.
The decision makes Pfizer's vaccine the first in the U.S.,to be authorized for children 15 and under.
The vaccine had previously been authorized only for those 16 and older.
U.S. President Joe Biden has called for swift mobilization to ready vaccinations immediately.
But the actual inoculations for this new group,will NOT begin until the CDC's recommendation,which comes on Wednesday.
If given the greenlight, another 5 percent of the U.S. population nearly 17 million more people will be eligible to get the shots.
Pfizer is also planning to seek approval for children between 2 and 11 years old in September.
Its vaccine safety and efficacy study in children ages 6 months to 11 years old is ongoing.
In the meantime, recent data from the UK shows, both Pfizer's and AstraZeneca's COVID-19 vaccine, reduces the risk of death from COVID-19 by up to 80 percent,after the first dose.
The figure rises to 97 percent for Pfizer's vaccine, after the second dose.
This is based on findings by Public Health England, which analyzed new COVID-19 cases,and people, by vaccination status, who died within 28 days after testing positive.
The study is the first 'real-world data' on COVID-19 vaccine protection against mortality.
Lee Kyung-eun, Arirang News.